Prevention of metabolic alterations by insulin supplements administered either before or after 2-h nocturnal interruption of CSII
- PMID: 3315513
- DOI: 10.2337/diacare.10.5.567
Prevention of metabolic alterations by insulin supplements administered either before or after 2-h nocturnal interruption of CSII
Abstract
To evaluate the efficacy of a bolus insulin injection to prevent the metabolic alterations induced by a 2-h nocturnal interruption of a continuous subcutaneous insulin infusion (CSII), nine type I (insulin-dependent) C-peptide-negative diabetic patients were studied from 2200 to 0800 h during two randomized tests. An insulin bolus (2.1 +/- 0.2 U) was administered via the pump either at 2300 h, just before CSII interruption, or at 0100 h, after reactivating the pump at its usual basal rate (1.05 +/- 0.11 U/h). The insulin bolus at 2300 h induced a significant rise in plasma free-insulin levels at 2400 h (+6.9 +/- 1.8 mU/L, P less than .01), resulting in an early and marked fall in blood glucose concentrations between 2300 and 0100 h (-2.7 +/- 0.5 mM, P less than .001), with hypoglycemic values in five patients. The insulin bolus at 0100 h counteracted the fall in plasma free-insulin levels observed between 2300 and 0100 h and significantly increased plasma insulin at 0200 h (+3.2 +/- 0.8 mU/L, P less than .01). Blood glucose concentrations that remained stable during the 2-h arrest of the pump fell significantly between 0100 and 0400 h (-2.1 +/- 0.5 mM, P less than .005). This fall rate was significantly lower than that measured within the 3 h after the insulin bolus given before CSII interruption but significantly higher than that observed in a reference control group of patients whose pump was functioning normally throughout the night.(ABSTRACT TRUNCATED AT 250 WORDS)
Similar articles
-
Metabolic alterations after a two-hour nocturnal interruption of a continuous subcutaneous insulin infusion.Diabetes Care. 1984 Jul-Aug;7(4):338-42. doi: 10.2337/diacare.7.4.338. Diabetes Care. 1984. PMID: 6381007 Clinical Trial.
-
Comparison of human regular and lispro insulins after interruption of continuous subcutaneous insulin infusion and in the treatment of acutely decompensated IDDM.Diabetes Care. 1998 May;21(5):817-21. doi: 10.2337/diacare.21.5.817. Diabetes Care. 1998. PMID: 9589247 Clinical Trial.
-
U-100 insulin gives some protection against metabolic deterioration due to CSII interruption.Diabetes Care. 1987 Nov-Dec;10(6):707-11. doi: 10.2337/diacare.10.6.707. Diabetes Care. 1987. PMID: 3322727
-
Continuous subcutaneous insulin infusion at 25 years: evidence base for the expanding use of insulin pump therapy in type 1 diabetes.Diabetes Care. 2002 Mar;25(3):593-8. doi: 10.2337/diacare.25.3.593. Diabetes Care. 2002. PMID: 11874953 Review.
-
[Continuous subcutaneous insulin infusion (CSII) in treating young diabetic patients].Przegl Lek. 2005;62(1):49-53. Przegl Lek. 2005. PMID: 16053222 Review. Polish.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials